Muscular Dystrophy
(asked on 7th November 2016) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what discussions his Department has had with NICE on a possible timetable for making Exon skipping therapy available to address Duchenne muscular dystrophy.
This question was answered on 14th November 2016
The Exon skipping therapy eteplirsen (Exondys 51) is currently being considered for referral to the National Institute for Health and Care Excellence’s (NICE) highly specialised technologies (HST) programme. Following discussion between NICE, NHS England and the Department as part of the topic selection process, NICE recently consulted stakeholders on its suitability for the HST process.